Corvus Total Assets from 2010 to 2024

CRVS Stock

USD 8.93 0.02 0.22%

Corvus Pharmaceuticals Total Assets yearly trend continues to be comparatively stable with very little volatility. Total Assets are likely to outpace its year average in 2024. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2014-12-31

Previous Quarter

64.6 M

Current Value

58.8 M

Quarterly Volatility

35 M

Yuan Drop

Covid

Check Corvus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Corvus Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 143.4 K, Interest Expense of 864.5 K or Selling General Administrative of 8.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.29. Corvus financial statements analysis is a perfect complement when working with Corvus Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Corvus Pharmaceuticals Correlation against competitors.

For more information on how to buy Corvus Stock please use our How to Invest in Corvus Pharmaceuticals guide.

Latest Corvus Pharmaceuticals' Total Assets Growth Pattern

Below is the plot of the Total Assets of Corvus Pharmaceuticals over the last few years. Total assets refers to the total amount of Corvus Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Corvus Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Corvus Pharmaceuticals' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Corvus Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 45.55 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Corvus Total Assets Regression Statistics

	Arithmetic Mean	65,013,963
	Geometric Mean	45,716,267
	Coefficient Of Variation	68.05
	Mean Deviation	37,584,770
	Median	68,525,440
	Standard Deviation	44,239,383
	Sample Variance	1957.1T
	Range	127.6M
	R-Value	0.51
	Mean Square Error	1550.7T
	R-Squared	0.26
	Significance	0.05
	Slope	5,085,122
	Total Sum of Squares	27399.7T

Corvus Total Assets History

	2024	68.5 M
	2023	45.6 M
	2022	68.2 M
	2021	109.5 M
	2020	85.5 M
	2019	83.6 M
	2018	118.2 M

Other Fundumenentals of Corvus Pharmaceuticals

Intangibles To Total Assets

Corvus Pharmaceuticals Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Net Receivables	Capital Surpluse	Net Invested Capital	Net Working Capital	Capital Stock	Long Term Investments
Total Assets		0.79	0.77	0.76	-0.71	-0.43	0.75	-0.15	0.17	0.93	-0.16	0.21	0.46	0.03	0.64	0.2	0.0	0.08	0.04
Total Stockholder Equity	0.79		0.99	0.83	-0.76	-0.56	0.68	-0.28	-0.47	0.67	0.28	0.33	0.6	-0.06	0.79	0.09	-0.12	0.19	-0.09
Net Tangible Assets	0.77	0.99		0.87	-0.74	-0.61	0.68	-0.33	-0.49	0.64	0.29	0.41	0.66	-0.12	0.84	0.0	-0.19	0.28	-0.19
Current Deferred Revenue	0.76	0.83	0.87		-0.43	-0.87	0.85	-0.62	-0.23	0.55	-0.02	0.63	0.81	-0.25	0.96	-0.33	-0.52	0.51	-0.48
Net Debt	-0.71	-0.76	-0.74	-0.43		0.01	-0.36	-0.19	0.22	-0.78	-0.38	0.09	-0.13	-0.05	-0.32	-0.49	-0.41	0.14	-0.24
Retained Earnings	-0.43	-0.56	-0.61	-0.87	0.01		-0.64	0.86	0.26	-0.14	0.19	-0.88	-0.84	0.19	-0.91	0.57	0.78	-0.78	0.75
Accounts Payable	0.75	0.68	0.68	0.85	-0.36	-0.64		-0.49	-0.01	0.59	-0.13	0.29	0.52	-0.37	0.77	-0.2	-0.37	0.13	-0.16
Short Term Investments	-0.15	-0.28	-0.33	-0.62	-0.19	0.86	-0.49		0.21	0.17	0.35	-0.8	-0.59	0.25	-0.68	0.48	0.77	-0.76	0.66
Total Liab	0.17	-0.47	-0.49	-0.23	0.22	0.26	-0.01	0.21		0.25	-0.68	-0.22	-0.3	0.1	-0.35	0.11	0.17	-0.18	0.18
Total Current Assets	0.93	0.67	0.64	0.55	-0.78	-0.14	0.59	0.17	0.25		0.03	-0.04	0.27	0.1	0.42	0.36	0.31	-0.16	0.24
Short Term Debt	-0.16	0.28	0.29	-0.02	-0.38	0.19	-0.13	0.35	-0.68	0.03		-0.24	0.03	-0.2	0.02	0.1	0.35	-0.25	0.14
Common Stock	0.21	0.33	0.41	0.63	0.09	-0.88	0.29	-0.8	-0.22	-0.04	-0.24		0.81	0.07	0.75	-0.56	-0.71	0.95	-0.8
Property Plant Equipment	0.46	0.6	0.66	0.81	-0.13	-0.84	0.52	-0.59	-0.3	0.27	0.03	0.81		-0.02	0.85	-0.58	-0.63	0.74	-0.64
Net Receivables	0.03	-0.06	-0.12	-0.25	-0.05	0.19	-0.37	0.25	0.1	0.1	-0.2	0.07	-0.02		-0.17	0.36	0.34	0.04	0.2
Capital Surpluse	0.64	0.79	0.84	0.96	-0.32	-0.91	0.77	-0.68	-0.35	0.42	0.02	0.75	0.85	-0.17		-0.36	-0.55	0.58	-0.51
Net Invested Capital	0.2	0.09	0.0	-0.33	-0.49	0.57	-0.2	0.48	0.11	0.36	0.1	-0.56	-0.58	0.36	-0.36		0.86	-0.62	0.82
Net Working Capital	0.0	-0.12	-0.19	-0.52	-0.41	0.78	-0.37	0.77	0.17	0.31	0.35	-0.71	-0.63	0.34	-0.55	0.86		-0.74	0.82
Capital Stock	0.08	0.19	0.28	0.51	0.14	-0.78	0.13	-0.76	-0.18	-0.16	-0.25	0.95	0.74	0.04	0.58	-0.62	-0.74		-0.89
Long Term Investments	0.04	-0.09	-0.19	-0.48	-0.24	0.75	-0.16	0.66	0.18	0.24	0.14	-0.8	-0.64	0.2	-0.51	0.82	0.82	-0.89

Click cells to compare fundamentals

About Corvus Pharmaceuticals Financial Statements

Corvus Pharmaceuticals shareholders use historical fundamental indicators, such as Total Assets, to determine how well the company is positioned to perform in the future. Although Corvus Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Corvus Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Corvus Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

		Last Reported	Projected for Next Year
	Total Assets	45.6 M	68.5 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Corvus Stock Analysis

When running Corvus Pharmaceuticals' price analysis, check to measure Corvus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corvus Pharmaceuticals is operating at the current time. Most of Corvus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corvus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corvus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corvus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC